Abstract
The countries of Central and Eastern Europe represent a total market of 285
million people and a combined GDP of US$3.3 trillion in 2008. Each country
report provides a comprehensive analysis of the pharmaceutical market,
including five-year market forecasts. For each country you will receive 4
completely updated reports sent quarterly, plus comprehensive report sent
annually.
The countries of Central and Eastern Europe represent a total market of 285
million people and a combined GDP of US$3.3 trillion in 2008
The impact of EU accession on the pharmaceutical market
In May 2004, five of the CEE markets in question joined the European Union.
Much of the pharmaceutical legislation within the region has therefore been
harmonised with that of the EU, although countries such as Poland are still in
the process of transposing EU directives into national law.
Romania and Bulgaria have also amended the relevant legislation and became
full EU members in January 2007. The implementation of GMP is also taking
place across most of the region and this will inevitably improve the quality
of overall production and lead to a rise in market values.
Variations in the quality of IP protection
The level of IP protection offered by the CEE nations varies across the
region, but the issue generally remains an international concern. Problems
that are commonly raised include a lack of transparency in IP procedures and
the lack of effective enforcement. Some countries, such as Bulgaria, have made
a lot of progress in improving the legal climate by strengthening patent laws
and extending the standard patent term to 20 years.
The dominance of the generics market
The demand for affordable drugs is the principal factor in the dominance of
the generics in the region. Despite recent improvements in patent protection,
legislation and effective enforcement are still needed in many countries where
counterfeiting of Western drugs continues. Generics production has managed to
remain strong in countries that are also home to the producers of branded
drugs. In the former Czechoslovakia for example, the merger of Leciva with
Slovakofarma enhanced generics production in 2003. However, as economies
develop the trend to importing higher value branded products can be seen.
These reports analyse the issues which matter
That is why Espicom Business Intelligence has published these new management
reports The Outlook for Pharmaceuticals in Central & Eastern Europe to 2013.
Each report provides individual and highly-detailed analysis of each market,
looking at the key regulatory, political, economic and corporate developments
in the wider context of market structure, service and access. The reports are
available individually, or as a discounted collection, and prices include 4
completely updated reports sent quarterly, plus a comprehensive report sent
annually. There are over 60 markets covered in the worldwide series.
11 Major Markets Covered!
- Bulgaria
- Hungary
- Russia
- Slovenia
- Croatia
- Poland Serbia
- Ukraine
- Czech Republic
- Romania
- Slovakia
| 
View Cart
